Abbott receives CE Mark for everolimus eluting coronary stent system

21 August 2012 (Last Updated August 21st, 2012 18:30)

Abbott, a healthcare company, has received the CE Mark in Europe for their Xience Xpedition everolimus eluting coronary stent system to treat coronary artery disease and is launching the product in CE Mark countries.

Abbott, a healthcare company, has received the CE Mark in Europe for their Xience Xpedition everolimus eluting coronary stent system to treat coronary artery disease and is launching the product in CE Mark countries.

Xience Xpedition has an improved stent delivery system which is designed with challenging coronary anatomies in mind.

Aarhus University Hospital, Skejby, Denmark, department of cardiology interventional cardiologist Dr Evald Christiansen said Xience Xpedition's deliverability enables complex coronary disease to be treated with confidence.

"Supported by robust clinical evidence from the Spirit family of trials, and with a broad range of indications, Xience Xpedition is an important advancement in drug eluting stent technology," Christiansen said.

Xience Xpedition is available with a range of indications, including use with a minimum duration of three months of dual anti-platelet therapy (DAPT).

The stent system is available in one of the broadest size matrices on the European market, from 2.25mm to 4mm diameter, uniquely including 3.25mm, and lengths from 8mm to 38mm.

Abbott Vascular chief medical officer and medical affairs divisional vice president Charles Simonton said the deliverability and range of sizes, along with the option to discontinue or interrupt DAPT after three months, has provided a wide range of options for treating complex coronary artery disease.

"With Xience Xpedition, Abbott continues its commitment to advancing drug eluting stent technology to improve product performance and patient outcomes," Simonton said.